AlphaMadera's AlphaVal page classifies Royalty Pharma plc as a Stable Earnings Power business and values it using P/Adj-EPS × Normalized Multiple, then compares the result to the current market price to flag RPRX as undervalued, fairly valued, or overvalued.

What is Royalty Pharma plc's fair value?

Fair value for RPRX comes from a P/Adj-EPS × Normalized Multiple model -- the approach AlphaVal selected for this company's Stable Earnings Power classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value RPRX?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. RPRX was classified as Stable Earnings Power and is valued using P/Adj-EPS × Normalized Multiple, built from RPRX's most recent reported fundamentals.

RPRX - Royalty Pharma plc

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $63.33 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Moderate

Trading 27.6% below fair value

Current Price $56.93

Bear Case $67.40 18.4% upside ($67.40 - $56.93) / $56.93 = 18.4% $5.62 × 12x P/E

Fair Value $78.64 38.1% upside ($78.64 - $56.93) / $56.93 = 38.1% $5.62 × 14x P/E

Bull Case $89.87 57.9% upside ($89.87 - $56.93) / $56.93 = 57.9% $5.62 × 16x P/E

Adjust Assumptions

P/E Multiple

14.0x

Adjusted EPS

5.62$

Key Value Driver

Normalized P/E multiple (14x base case)

Terminal Value % of EV

Implied Market Multiple 10.1x

Market is pricing in (growth)

Plain-Language Summary

Applying a 14x P/E to adjusted EPS of $5.62, the base-case value is $78.64 per share. DDM cross-check: $28.15.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (11 analysts) $63.33

Analyst Range $57.00 – $67.00

Divergence from AlphaVal 24%

Warnings

⚠ The company's reported profits differ from official accounting profits by 212%. Check what costs are being left out of the adjusted number.

ℹ Dividend-based valuation: $28.15 (below our primary estimate by 64%). Large gaps may signal the dividend doesn't reflect full earning power.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples